
Between a Rock and a Hard Plaque: The Relationship Between LDL-C and ASCVD Risk and Improving Patient Outcomes with PCSK9 Inhibitors
Pharmacists can bridge the gap in ASCVD care with lipid screening, optimization of LDL-C lowering medication therapy, and improving medication adherence. In this program, experts will review updated guideline recommendations for ASCVD risk assessment and treatment; explore statin and nonstatin medications including current and emerging PSK9 inhibitors; describe strategies for overcoming barriers to achieving LDL-C thresholds; and expand on strategies for increased patient engagement and shared decision-making to optimize outcomes.
Wednesday, Dec. 10
11:30 a.m. - 1 p.m. PT (2:30 - 4 p.m. ET)
Symposium Location: Islander Ballroom G, Lower Level, Mandalay Bay North Convention Center
Come early! Seating is limited and provided on a first-come, first-served basis.
Can't make it to Las Vegas? Tune into the Free Live Webinar Broadcast.
Registration is required for the webinar.
Speakers

Joseph Saseen, PharmD, FASHP, MNLA, BCPS, BCACP, Activity Chair
Associate Dean for Clinical Affairs, Professor, Department of Clinical Pharmacy; Professor, Department of Family Medicine
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus
Aurora, Colorado
Joseph Saseen is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine at the University of Colorado Anschutz Medical Campus. Dr. Saseen’s academic and clinical practice contributions focus on cardiovascular risk reduction and population health. He was a member of the 2018 AHA/ACC/Multisociety cholesterol management guideline writing committee and is a member of the upcoming 2026 guideline. His scholarly work includes over 200 peer-reviewed publications and book chapters.

Bruce A. Warden, PharmD, BCPS, CLS, FNLA, FASPC
Clinical Pharmacist, General Cardiology
Knight Cardiovascular Institute, Oregon Health & Science University
Portland, Oregon
Bruce A. Warden is a Cardiovascular Pharmacy Specialist at the General Cardiology Clinic, Knight Cardiovascular Institute, Oregon Health & Science University (OHSU) in Portland, Oregon. He received his PharmD degree from the Oregon State University / OHSU and completed a one year post-graduate pharmacy practice residency at OHSU. Dr. Warden’s clinical practice area is cardiology, during which he has practiced in the inpatient acute care wards, cardiovascular intensive care unit and ambulatory settings including preventive cardiology, and most recently, the general cardiology clinic. Within these roles, he assists in the management of acute and chronic cardiovascular conditions, transitions of care, pharmacotherapy optimization, patient and provider education and student and resident development. Dr. Warden’s clinical and research interests include atherosclerotic cardiovascular disease risk reduction through cardiometabolic optimization, with a focus in lipid and weight management.
Target Audience
This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, specialty pharmacies, ambulatory clinics, and community settings who manage patients at high risk for ASCVD or who have clinical ASCVD.
Learning Objectives
- Analyze the role of LDL-C in ASCVD and the importance of achieving LDL-C thresholds to reduce the risk of ASCVD events.
- Prioritize lipid screening and risk stratification for patients at high risk for ASCVD and with clinical ASCVD, including patients with heterozygous familial hypercholesterolemia, at-risk populations, and patients with high unmet needs.
- Examine benefits and risks of current and emerging LDL-C lowering pharmacotherapies.
- Apply current guideline-based recommendations to the treatment of patients at high risk for ASCVD and with clinical ASCVD who are eligible for nonstatin therapies including PCSK9 inhibitors.
Agenda
- 11:30 a.m. – Welcome and Introductions
Joseph Saseen - 11:35 a.m. – Overview of Atherosclerosis
Bruce A. Warden - 11:45 p.m. – Evidence-based Management of Hypercholesterolemia
Joseph Saseen - 12:00 p.m. – Statin and Nonstatin Medications
Joseph Saseen - 12:20 p.m. – Achieving Recommended LDL-C Thresholds to Reduce ASCVD Event Risk
Bruce A. Warden - 12:50 p.m. – Faculty Discussion, Questions and Answers
All Faculty
Accredited for CPE
ACPE #: 0204-0000-25-417-L01-P
CE Credit: 1.5 contact hours (0.15 CEUs)
Activity Type: Application-based
Activity Fee: No charge
To Claim CE for the webinar, enter the CE code announced during the activity and complete the evaluation.
![]() |
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. |
![]() |
Provided by ASHP.
Supported by an educational grant from Merck. For questions and assistance to participate, contact us. |